Estrella Immunopharma, Inc. develops clinical-stage ARTEMIS T-cell therapies for cancer and autoimmune diseases. Company updates center on its CD19-targeted lead candidate EB103, the CD19/CD22-targeted EB104 program, and STARLIGHT-1 clinical disclosures in B-cell non-Hodgkin lymphoma and other B-cell malignancy settings.
Recurring news also covers conference presentations, clinical data releases, financing transactions, analyst coverage, Nasdaq listing matters, and governance developments. Estrella's public securities include Nasdaq-listed common stock under ESLA and warrants under ESLAW.
Estrella Immunopharma (Nasdaq: ESLA) announced a late-breaking oral presentation of Phase 1 STARLIGHT-1 data for EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings. The presentation (Final Paper LBA-1, Abstract 29644) is scheduled for Feb 7, 2026, 3:15 p.m. MST and the abstract will be posted Feb 4, 2026 at 12:00 a.m. CT.
Presenting author: Naseem Esteghamat, MD MS. The study evaluates CD19-redirected ARTEMIS T cells in aggressive B-cell non-Hodgkin lymphoma.
Estrella Immunopharma (NASDAQ: ESLA) closed a registered direct offering and a concurrent private placement on January 6, 2026, raising approximately $8.0 million aggregate gross proceeds.
The company issued 4,063,290 common shares and 1,000,000 pre-funded warrants; it also issued common warrants to purchase up to 7,594,935 shares. The combined price per share with warrant was $1.58 (pre-funded $1.57999). Pre-funded warrants carry a $0.00001 exercise price and no expiration; common warrants have a $1.39 strike and five-year term. Net proceeds are planned for general corporate purposes and to advance the lead program, EB103, through Phase II.
Estrella Immunopharma (NASDAQ: ESLA) announced definitive agreements for a registered direct offering and a concurrent private placement, together expected to raise approximately $8.0 million. The transaction, priced at-the-market under Nasdaq rules, consists of 5,063,290 Common Units (or Pre-Funded Units) and a total of 7,594,935 PIPE Common Warrants, each exercisable at $1.39. The offering price per Common Unit is $1.58 (Pre-Funded Unit: $1.5799). The Pre-Funded Warrants are immediately exercisable. Closing is expected on or about January 6, 2026. Net proceeds will be used for general corporate purposes and working capital; Aegis Capital is sole placement agent.
Estrella (NASDAQ: ESLA) announced an independent DSMB recommended advancing the STARLIGHT-1 trial of EB103 into Phase II at the Recommended Phase II Dose (RP2D).
The Phase I dose‑escalation (n=9) reported no treatment-related serious adverse events and the high‑dose cohort achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients, including high‑risk subjects such as one with CNS lymphoma. The expansion phase will evaluate safety and preliminary efficacy at RP2D across multiple centers and inform the pivotal trial strategy (NCT06343311).
Estrella Immunopharma (NASDAQ: ESLA) completed the second dose cohort of the Phase I portion of its STARLIGHT-1 Phase I/II trial of EB103, a CD19-redirected ARTEMIS T-cell therapy for advanced B-cell non-Hodgkin’s lymphoma.
Key results: the cohort achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients, including a patient with CNS lymphoma, and no treatment-related serious adverse events were reported. A Data and Safety Monitoring Board will review cumulative data to determine the Recommended Phase II Dose (RP2D) before dose expansion. Trial identifier: NCT06343311.
Estrella Immunopharma (NASDAQ: ESLA) announced it has regained compliance with Nasdaq listing requirements after addressing prior deficiencies. The company said Nasdaq confirmed compliance with the minimum bid price requirement (Rule 5550(a)(2)) and the minimum market value of listed securities requirement (Rule 5550(b)(2)), and that both matters are closed.
The company attributed the outcome to successful efforts to improve its balance sheet, including raising new capital to continue development of its CD19 and CD22-targeted ARTEMIS T-cell therapies. The Nasdaq letters were received on September 23, 2025, with the compliance status disclosed in an 8-K filed on September 29, 2025.
Estrella Immunopharma (NASDAQ: ESLA) has initiated dosing of the first patient in the second cohort of its Phase I/II STARLIGHT-1 trial, evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy for Advanced B-Cell Non-Hodgkin's Lymphomas (NHL). The second cohort will test a higher dose level following successful safety data from the first cohort, where no dose-limiting toxicities or treatment-related serious adverse events were observed.
The company's CEO, Cheng Liu, highlighted that EB103 shows promise in addressing limitations of traditional CAR-T therapies, particularly for high-risk patients with HIV-associated lymphoma and central nervous system lymphoma, who are typically excluded from existing CAR-T treatments.
Estrella Immunopharma (NASDAQ: ESLA) has received a Buy rating with a $14.00 price target from CB Capital Partners, who will serve as financial advisor for their Initiation Research Report. The analysis focuses on Estrella's proprietary ARTEMIS® T-cell platform and their lead candidate EB103.
The report highlights three key aspects: 1) Superior safety and efficacy of EB103, showing high response rates without severe cytokine release syndrome or neurotoxicity syndrome; 2) Expanded patient access, particularly for high-risk non-Hodgkin lymphoma patients including those with HIV-associated and CNS lymphoma; 3) Strong strategic appeal due to the platform's innovative design and potential for expedited regulatory pathways.